News and Events

Hoosier Cancer Research Network is proud to share a recap of our experience at the 2025 American Society of Clinical Oncology® (ASCO) Annual Meeting. The review features highlights, key photos, notable moments, and insights into how we’re carrying the momentum of ASCO forward. About Hoosier Cancer Research Network: Hoosier Cancer Research Network conducts innovative cancer clinical trials in collaboration with more than 100 academic and community clinical research sites across the United States. Our studies are designed by cancer researchers...

Hoosier Cancer Research Network has released a new report, “Investigator-Initiated Oncology Trials: Trends, Challenges, and Opportunities,” that captures the experience and perspectives of more than 130 researchers across its nationwide network. The findings highlight key trends shaping investigator-initiated oncology research and the operational, institutional, and funding challenges researchers face in today’s environment. 

We are proud to see our CEO, Brian Stemme, featured in an Indiana Business Journal article as a trusted expert in Indiana’s life sciences ecosystem.

The University of Notre Dame will confer an honorary Doctor of Science degree on Hoosier Cancer Research Network (HCRN) co-founder Rafat Ansari, MD, at its 180th University Commencement Ceremony on May 18. A South Bend Community Hall of Fame inductee, Dr. Ansari has been a community leader in hematology and oncology for more than four decades. As a co-founder of HCRN, he was instrumental in streamlining the clinical trials process for cancer patients. Read more: https://news.nd.edu/news/notre-dame-to-confer-seven-honorary-degrees-at-commencement/

Hoosier Cancer Research Network (HCRN) is set to participate in the American Society of Clinical Oncology® (ASCO) 2025 Annual Meeting in Chicago from May 30 to June 3. During the event, four HCRN studies will be presented, working group meetings will take place, and HCRN will host a joint reception with the Big Ten Cancer Research Consortium. The HCRN team will also be present in the exhibit hall at booth # 36117.

  Julie Russell Dilts, JD, has joined the Hoosier Cancer Research Network (HCRN) team as general counsel. Julie brings a wealth of expertise in various legal and regulatory areas, as well as a passion for the mission of HCRN.

Hoosier Cancer Research Network (HCRN) launched an updated website today with new features and a modernized design.

Researchers participating in the Hoosier Cancer Research Network GU16-260 study have published a correlative analysis in Cancer Discovery. The analysis, led by David A. Braun, MD, PhD, of Yale Cancer Center; Catherine J. Wu, MD, of the Dana-Farber Cancer Institute; and Michael B. Atkins, MD, of Georgetown Lombardi Comprehensive Cancer Center, found that the presence of tertiary lymphoid structures and exhausted tissue-resident T cells determines clinical response to PD-1 blockade in renal cell carcinoma. Congratulations to all co-authors and study teams...

Hoosier Cancer Research Network (HCRN) is set to participate in ASCO GU 2025 in San Francisco from February 13-15, 2025, with HCRN-GU16-243 being presented as a Rapid Oral Abstract, and several other studies as poster presentations.

A Hoosier Cancer Research Network abstract, HCRN-LUN21-497, titled, “Results from a phase II study of GT103 in combination with pembrolizumab in refractory, metastatic non-small cell lung cancer,” was presented at SITC 2024 by Jeffrey Clarke, MD, of Duke University.